CD274 and cancer: Systemic administration of PD-L1/PD-1 blocking antibodies results in a strong potentiation of the anti-tumor capacities of T cells, as many preclinical studies have shown for some time.4–7 Since 2012, PD-L1/PD-1 blockade therapies have proven efficacious for the treatment of many human cancers.